The VertiGO! Trial protocol: A prospective, single-center, patient-blinded study to evaluate efficacy and safety of prolonged daily stimulation with a multichannel vestibulocochlear implant prototype in bilateral vestibulopathy patients

PLoS One. 2024 Mar 28;19(3):e0301032. doi: 10.1371/journal.pone.0301032. eCollection 2024.

Abstract

Background: A combined vestibular (VI) and cochlear implant (CI) device, also known as the vestibulocochlear implant (VCI), was previously developed to restore both vestibular and auditory function. A new refined prototype is currently being investigated. This prototype allows for concurrent multichannel vestibular and cochlear stimulation. Although recent studies showed that VCI stimulation enables compensatory eye, body and neck movements, the constraints in these acute study designs prevent them from creating more general statements over time. Moreover, the clinical relevance of potential VI and CI interactions is not yet studied. The VertiGO! Trial aims to investigate the safety and efficacy of prolonged daily motion modulated stimulation with a multichannel VCI prototype.

Methods: A single-center clinical trial will be carried out to evaluate prolonged VCI stimulation, assess general safety and explore interactions between the CI and VI. A single-blind randomized controlled crossover design will be implemented to evaluate the efficacy of three types of stimulation. Furthermore, this study will provide a proof-of-concept for a VI rehabilitation program. A total of minimum eight, with a maximum of 13, participants suffering from bilateral vestibulopathy and severe sensorineural hearing loss in the ear to implant will be included and followed over a five-year period. Efficacy will be evaluated by collecting functional (i.e. image stabilization) and more fundamental (i.e. vestibulo-ocular reflexes, self-motion perception) outcomes. Hearing performance with a VCI and patient-reported outcomes will be included as well.

Discussion: The proposed schedule of fitting, stimulation and outcome testing allows for a comprehensive evaluation of the feasibility and long-term safety of a multichannel VCI prototype. This design will give insights into vestibular and hearing performance during VCI stimulation. Results will also provide insights into the expected daily benefit of prolonged VCI stimulation, paving the way for cost-effectiveness analyses and a more comprehensive clinical implementation of vestibulocochlear stimulation in the future.

Trial registration: ClinicalTrials.gov: NCT04918745. Registered 28 April 2021.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Bilateral Vestibulopathy*
  • Cochlear Implants* / adverse effects
  • Cross-Over Studies
  • Humans
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Single-Blind Method

Associated data

  • ClinicalTrials.gov/NCT04918745

Grants and funding

B.L.V., E.D. and A.v.S. were and will be supported through funding of MED-EL and ZonMw. B.V. and S.C.J.v.B. were and will be supported through funding of MED-EL, Heinsius Houbolt fonds and Stichting De Weijerhorst. E.L. is funded by the Klinische onderzoeks- en opleidingsraad (KOOR) of the University Hospitals Leuven. N.G., A.P.F and R.B. received several research and travel grants from MED-EL. The funders had no role in study design and will not have a role in data collection, data analysis, interpretation of data, decision to publish, or preparation of the manuscript. The remaining authors declare that research will be conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.